ALUR vs. NSPR, APT, TMDIF, CTSO, LUCD, APYX, INO, MODD, BLAC, and BDMD
Should you be buying Allurion Technologies stock or one of its competitors? The main competitors of Allurion Technologies include InspireMD (NSPR), Alpha Pro Tech (APT), Titan Medical (TMDIF), Cytosorbents (CTSO), Lucid Diagnostics (LUCD), Apyx Medical (APYX), Inovio Pharmaceuticals (INO), Modular Medical (MODD), Bellevue Life Sciences Acquisition (BLAC), and Baird Medical Investment (BDMD). These companies are all part of the "medical equipment" industry.
Allurion Technologies vs.
Allurion Technologies (NYSE:ALUR) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and community ranking.
In the previous week, InspireMD had 4 more articles in the media than Allurion Technologies. MarketBeat recorded 4 mentions for InspireMD and 0 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 1.00 beat InspireMD's score of 0.11 indicating that Allurion Technologies is being referred to more favorably in the media.
Allurion Technologies received 3 more outperform votes than InspireMD when rated by MarketBeat users. Likewise, 87.50% of users gave Allurion Technologies an outperform vote while only 4.55% of users gave InspireMD an outperform vote.
21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 22.4% of Allurion Technologies shares are held by insiders. Comparatively, 29.7% of InspireMD shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Allurion Technologies has a beta of -0.69, indicating that its share price is 169% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
InspireMD has lower revenue, but higher earnings than Allurion Technologies. InspireMD is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.
Allurion Technologies has a net margin of -71.24% compared to InspireMD's net margin of -413.96%. Allurion Technologies' return on equity of 0.00% beat InspireMD's return on equity.
Allurion Technologies currently has a consensus target price of $54.17, indicating a potential upside of 870.73%. InspireMD has a consensus target price of $4.75, indicating a potential upside of 59.40%. Given Allurion Technologies' higher probable upside, research analysts plainly believe Allurion Technologies is more favorable than InspireMD.
Summary
Allurion Technologies beats InspireMD on 9 of the 16 factors compared between the two stocks.
Get Allurion Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALUR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Allurion Technologies Competitors List
Related Companies and Tools
This page (NYSE:ALUR) was last updated on 2/11/2025 by MarketBeat.com Staff